Salute e Benessere

VENDEE GLOBE: ALAN ROURA, HUBLOT AND THE WHOLE OF SWITZERLAND READY TO TAKE ON…

A date with the oceans awaits. At 13:02 on Sunday 10th November, Alan Roura will officially be setting off on his third consecutive Vendée Globe aboard the IMOCA Hublot, adding his name and that of the prestigious watch manufacture to the annals of Swiss sporting history! A date with the oceans awaits. At 13:02 on Sunday 10 thNovember,Alan Rourawill officially be setting off on his third consecutive Vendée Globe aboard the IMOCA Hublot, adding his name and that of the prestigious watch...
PR Newswire
11/11/2024

French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials…

Global Investments Pave Way for Breakthrough Treatment for Type 2 Diabetes AdipoPharma, a biotech company headquartered in France with offices in the US and Belgium developing a novel and promising Type 2 diabetes drug, announced today that it has successfully secured the funding needed to begin Phase 1 clinical trials. The company is slated to begin clinical trials in the U.S. in mid-2025. This crucial funding will enable AdipoPharma to accelerate its clinical development, marking a...
Nasdaq GlobeNewswire
11/11/2024

Idorsia is advancing the treatment of hypertension with new data at the 2024…

Allschwil, Switzerland – November 11, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist (ERA) for the treatment of systemic hypertension, will be presented at the American Heart Association (AHA) annual Scientific Sessions 2024, taking place in Chicago, Illinois, November 16–18, 2024. AHA Scientific Sessions is the preeminent conference of its kind featuring top global leaders in cardiovascular and brain health...
Nasdaq GlobeNewswire
11/11/2024

Whole Genome Sequencing Market to Be Worth $7.17 Billion by 2031 - Exclusive…

Whole Genome sequencing is a method for analyzing entire genome. It determines precise order of every base pair in a genome. Whole genome sequencing provides information about protein coding and non-coding regions. With the advent of next generation sequencing whole genome sequencing have become cheaper, faster and powerful. Whole genome sequencing has wide applications including genetic disease research, cancer research, genotyping and epidemiology. Whole Genome sequencing is a method for...
PR Newswire
11/11/2024

Transactions in Zealand Pharma shares and/or related securities by persons…

Company announcement – No. 50 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsCopenhagen, Denmark, November 11, 2024 –Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand Pharma's shares...
Nasdaq GlobeNewswire
11/11/2024

Synthetic Biology Market to Hit USD 31.52 Billion by 2029 with 20.6% CAGR |…

Browse in-depth TOC on "Synthetic Biology Market" Browse in-depth TOC on "Synthetic Biology Market" 722 - Tables 46 - Figures 536 - Pages The tool segment is segmented into oligonucleotides & synthetic DNA, enzymes, cloning technology kits, chassis organisms, xeno nucleic acids and synthetic cells. The oligonucleotides & synthetic DNA segment dominated tool segment in terms of market share and CAGR. The large share of this segment is attributed to the rising demand…
PR Newswire
11/11/2024

Topical Drug Delivery Market is expected to generate a revenue of USD 177.97…

As the demand for localized treatment options continues to rise, topical drug delivery systems are gaining prominence across the pharmaceutical industry. From dermatology to pain management and beyond, this market is witnessing significant advancements, driven by technological innovations and a growing preference for non-invasive treatment methods. As the demand for localized treatment options continues to rise, topical drug delivery systems are gaining prominence across the pharmaceutical…
PR Newswire
11/11/2024

PathogenDx Applauded by Frost & Sullivan for Enabling Early and Precise UTI…

PathogenDx's D3 Array™-UTI contains molecular probes associated with specific pathogens, and ARG gene markers. Each array has 324 to 576 probes printed in a well. Compared to qPCR assays, the D3 Array-UTI offers greater accuracy, lower costs, and higher throughput. The entire process can complete 48 samples in about 6 to 7 hours. While some competitors can complete their process in 5 hours, they are limited to between 8 and 14 samples. The D3 Array™ provides a greater binding area compared to…
PR Newswire
11/11/2024

Airdoc is committed to the early screening and predictive analysis of chronic…

AI-FD16H is a fully automatic mydriasis-free fundus camera specially designed and developed for artificial intelligence fundus image analysis. It is non-invasive and suitable for rapid screening, with automatic pupil tracking, positioning, focusing and shooting. The AI seamlessly connects to capture images and conducts real-time analysis. It has high-definition imaging of 12 million pixels and a large field of view of 50°. The nine-point internal fixation covers a wider field of vision. It has a…
PR Newswire
11/11/2024

Economist Impact's 4th edition Future of Health Asia to empower healthcare…

Healthcare leaders continue to face challenges to mitigate vulnerabilities, manage sustainability, digitise and improve the value of health ecosystems to make them accessible and inclusive. Developments in the field of AI are presenting opportunities and uncertainties. This event brings together more than 300 health leaders to shape the future use of AI. Healthcare leaders continue to face challenges to mitigate vulnerabilities, manage sustainability, digitise and improve the value of health...
PR Newswire
11/11/2024

ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical…

The Phase 2b clinical trial (CTR20231695) was a multicenter, randomized, double-blind, placebo-controlled, dose-finding study designed to evaluate the efficacy and safety of bi-weekly (Q2W) and once-weekly (QW) dosing regimens of GZR18 injection. The study enrolled a total of 340 participants, all of whom were obese (BMI≥28 kg/m²) or overweight (BMI≥24 kg/m²) with at least one weight-related comorbidity and whose weight was poorly controlled by diet and exercise. Participants were randomly…
PR Newswire
11/11/2024

Buyback of Class B shares in Essity during week 45, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
11/11/2024

Resolution Therapeutics Announces New Clinical and Preclinical Data Showcasing…

– RTX001 has recently entered into a Phase 1/2 interventional study in end-stage liver disease. – RTX001 has recently entered into a Phase 1/2 interventional study in end-stage liver disease. EDINBURGH, ScotlandandLONDON , Nov. 11, 2024 /PRNewswire/ -- Resolution Therapeutics Limited ("Resolution" or "Company"), a clinical-stage biopharmaceutical company spun out of theUniversity of Edinburghpioneering regenerative macrophage therapy in inflammatory and fibrotic diseases,...
PR Newswire
11/11/2024

STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3…

The Phase 1 clinical study enrolled 42 patients across five dose escalation cohorts ranging from 60mg to 200mg and explored daily and thrice weekly oral dosing regimens. Data presented at SITC follows the Company's presentation at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in October 2024. The Phase 1 clinical study enrolled 42 patients across five dose escalation cohorts ranging from 60mg to 200mg and explored daily and thrice weekly oral dosing regimens...
PR Newswire
11/11/2024

Huion's Early Black Friday Deals Go Live on Nov 11

Kamvas Pro 19 Kamvas Pro 19 Take the US site of Huion's official store as an example (to check specific discounts for your location, please visit the corresponding site in your area). During the sale, the price of Kamvas Pro 19 will drop to$879, saving you$220off its MSRP of$1,099. This is a record-low price since its release. Featuring the latest Huion PenTech 4.0 technology, Kamvas Pro 19 boasts16Klevels of pressure sensitivity, ensuring more delicate and smooth line...
PR Newswire
11/11/2024

EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver…

EBX-102 demonstrated proof-of-principle across multiple microbiome assessments, inflammatory biomarkers and clinical assessments, supporting its continued development as the first microbial therapy for individuals with liver disease Glasgow, Scotland – 11 November 2024.EnteroBiotix Limited ('EnteroBiotix' or the 'Company'), a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced positive results from its...
Nasdaq GlobeNewswire
11/11/2024

Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)

Right to participate and registration Right to participate and registration (A) Participation at the meeting venue A person who wishes to attend the meeting venue in person or by proxy must If the shareholder is represented by proxy, a written and dated power of attorney signed by the shareholder shall be issued for the proxy. Proxy forms are available at the company's websitewww.sobi.com. If the power of attorney has been issued by a legal entity, a registration certificate or...
PR Newswire
11/11/2024

Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product…

OMPD will offer Neurizon a range of attractive incentives for NUZ-001. These include reduced regulatory fees, free protocol assistance, and, importantly, 10 years of market exclusivity in the European Union (EU). During the exclusivity period, the EMA and the EU Member States will not accept another marketing authorisation application for a similar medicinal product in the same therapeutic indication. OMPD will offer Neurizon a range of attractive incentives for NUZ-001. These include reduced...
PR Newswire
11/11/2024

Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second…

Nine-month Results Remain On Track for Net ProfitAd Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, November 11, 2024-Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional third quarter net results decreased significantly compared to the second quarter 2024. The provisional result for the third...
Nasdaq GlobeNewswire
11/11/2024

China's Pioneer Hemodialysis Company to Attend MEDICA 2024

At MEDICA, the company will showcase three flagship hemodialysis machines: At MEDICA, the company will showcase three flagship hemodialysis machines: "Over the years, our dedicated SWS team has transformed the company from a start-up into a leader in the blood purification equipment industry. SWS epitomizes the rise of Chinese medical device enterprises globally. We are committed to fostering a brand that empowers kidney patients worldwide" GAO Guangyong, Chairman of SWS Medical. Based…
PR Newswire
11/11/2024

TB Alliance Joins Indonesia's High-Level Meeting on TB

The meeting will feature a series of expert panels that will delve into comprehensive analyses of the current state of TB, alongside forward-looking strategies that prioritize groundbreaking solutions in treatment, diagnostics, and vaccine development. Representing TB Alliance, Dr. Mel Spigelman, President and CEO, Dr. Eugene Sun, Senior Vice President of R&D, and Sandeep Juneja, Senior Vice President of Market Access, will speak on panels addressing the transformation of TB research and…
PR Newswire
11/11/2024

KFSHRC's New US Patent Opens New Frontiers for Breast Cancer Treatment

RIYADH, Saudi Arabia, Nov.10, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) announced a significant advancement in stem cell science, securing a U.S. patent for an innovative method that holds promise for breast cancer treatment and regenerative medicine.This innovative approach, developed by KFSHRC researchers Abdelilah Aboussekhra, Huda H. Al-Khalaf, and Hazem Ghebeh, involves transforming regular breast cells into multipotent stem cells...
Nasdaq GlobeNewswire
10/11/2024

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the…

Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics' TCR-T PRAME franchise to target solid cancersACTengine® IMA203 demonstrates 54% cORR, 12.1 months mDOR and 6 months mPFS in heavily pretreated metastatic melanoma patients and >1-year mPFS in patients with deep responses; Company plans to start its randomized-controlled Phase 3 SUPRAME trial in December 2024 to evaluate...
Nasdaq GlobeNewswire
08/11/2024

Teva to Present at the Jefferies London Healthcare Conference

To access a live webcast of the presentation, visit Teva's Investor Relations website athttps://ir.tevapharm.com/Events-and-Presentations.An archived version of the webcast will be available within 24 hours after the end of the live discussion. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded...
Nasdaq GlobeNewswire
08/11/2024
Altri  Comunicati